Endovascular Stenting for Vertebral Artery Stenosis Article

Full Text via DOI: 10.1016/j.jacc.2009.08.069 PMID: 20152558 Web of Science: 000274232000003

Cited authors

  • Jenkins, J. Stephen; Patel, Samir N.; White, Christopher J.; Collins, Tyrone J.; Reilly, John P.; McMullan, Paul W.; Grise, Mark A.; Grant, Arthur G.; Ramee, Stephen R.

Abstract

  • Objectives The aim of this study was to demonstrate the safety and long-term durability of catheter-based therapy for symptomatic vertebral artery stenosis (VAS).; Background Symptomatic VAS carries with it a 5-year 30% to 35% risk of stroke. The 2-year mortality approaches 30% for medically managed strokes involving the posterior circulation. Surgical bypass is rarely performed, due to high morbidity and mortality. Endovascular revascularization with primary stenting offers an attractive treatment option for these patients.; Methods One-hundred five consecutive symptomatic patients (112 arteries, 71% male) underwent stent placement for extracranial (91%) and intracranial (9%) VAS from 1995 to 2006. Fifty-seven patients (54%) had bilateral VAS, 71 patients (68%) had concomitant carotid disease, and 43 patients (41%) had a prior stroke.; Results Procedural and clinical success was achieved in 105 (100%) and 95 (90.5%) patients, respectively. One-year follow-up was obtained in 87 (82.9%) patients, of which 69 patients (79.3%) remained symptom-free. At 1 year, 6 patients (5.7%) had died and 5 patients (5%) had a posterior circulation stroke. Target vessel revascularization occurred in 7.4% at 1 year. At a median follow-up of 29.1 months (interquartile range 12.8 to 50.9 months), 13.1% underwent target vessel revascularization, 71.4% were alive, and 70.5% remained symptom-free.; Conclusions In experienced hands, stenting for symptomatic VAS can be accomplished with a very high success rate (100%), with few periprocedural complications, and is associated with durable symptom resolution in the majority (approximately 80%) of patients. We conclude that endovascular stenting of vertebral artery atherosclerotic disease is safe and effective compared with surgical controls and should be considered first-line therapy for this disease. (J Am Coll Cardiol 2010; 55: 538-42) (c) 2010 by the American College of Cardiology Foundation

Authors

Publication date

  • 2010

Published in

International Standard Serial Number (ISSN)

  • 0735-1097

Start page

  • 538

End page

  • 542

Volume

  • 55

Issue

  • 6